Japan has approved its first biosimilar rival to the blockbuster Humira (adalimumab) brand. Mylan is set to market the Fujifilm Kyowa Kirin Biologics biosimilar locally, having already launched the product as Hulio in Europe under a 2018 partnership that was expanded globally in 2019.
Japan Approves First Humira Biosimilar
Mylan Will Market Fujifilm Kyowa Kirin’s Adalimumab Rival In Japan
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
